CD7 and neoplasm: In this trial, one patient experienced treatment failure due to the absence of CD7 expression in bone marrow tumor cells, and one patient developed a CD7 negative relapse.10 Tumor recurrence of CD7- was also reported in a recent clinical trial (NCT04004637) using autologous anti-CD7 CAR-T cells to treat CD7+ r/r T-lymphocytic leukemia/lymphoma.11